Description
**Selected for 2025 Doody's Core Titles® in Toxicology**A Comprehensive Guide to Toxicology in Nonclinical Drug Development, Third Edition is a valuable reference providing a complete understanding of all aspects of nonclinical toxicology in pharmaceutical research. This updated edition has been expanded and re-developed covering a wide-range of toxicological issues in small molecules and biologics. Topics include ADME in drug discovery, pharmacokinetics, toxicokinetics, formulations, and genetic toxicology testing. The book has been thoroughly updated throughout to reflect the latest scientific advances and includes new information on antiviral drugs, anti-diabetic drugs, immunotherapy, and a discussion on post-pandemic drug development challenges and opportunities. This is an essential and practical resource for all toxicologists involved in nonclinical testing in industry, academic, and regulatory settings.- Provides updated, unique content not covered in one comprehensive resource, including chapters on stem cells, antiviral drugs, anti-diabetic drugs, and immunotherapy- Includes the latest international guidelines for nonclinical toxicology in both small and large molecules- Incorporates practical examples in order to illustrate day-to-day activities and expectations associated with working in nonclinical toxicology
Table of Contents
1. IntroductionSection I. Drug Discovery, Metabolism, and Pharmacokinetics2. Critical Aspects of Integrated Nonclinical Drug Development: Concepts, Strategies, and Potential Pitfalls3. ADME in Drug Discovery4. Pharmacokinetics and Toxicokinetics5. Secondary Pharmacology Screening in Drug DiscoverySection II. Toxicological Studies and Ind Application, and First In-Human Clinical Trial6. Acute, Subacute, Subchronic, and Chronic General Toxicity Testing for Preclinical Drug Development7. Genetic Toxicology Testing8. Contemporary Practices in Core Safety Pharmacology Assessments9. Preparation of a Preclinical Dossier to Support an Investigational New Drug (IND) Application and First-In-Human Clinical Trial10. Developmental and Reproductive Toxicology11. Juvenile Testing to Support Clinical Trials in Pediatric Population12. Preclinical Evaluation of Carcinogenicity Using Standard-Bred and Genetically Engineered Rodent Models13. Current Strategies for Abuse Liability Assessment of New Chemical EntitiesSection III. Clinical Pathology, Histopathology, and Biomarkers14. Clinical Pathology15. Best Practice in Toxicological Pathology16. Molecular Pathology: Applications in Nonclinical Drug Development17. Biomarkers in Nonclinical Drug DevelopmentIV. Biostatistics, Regulatory Toxicology, and Role of Study Directors18. Biostatistics for Toxicologists19. Regulatory Toxicology20. Role of Study Director and Study Monitor in Drug Development Safety StudiesSection V. Specialty Route of Administration21. Infusion Toxicology and Techniques22. Photosafety AssessmentSection VI. Nonclinical Development of Monoclonal Antibodies, Stem Cells, Oncogenic and Non-Oncogenic Drugs, Oligonucleotides, and Vaccines23. Preclinical Development of Monoclonal Antibodies24. Nonclinical Safety Assessment of Cell-Based Therapies25. Nonclinical Development of Antiviral Drugs26. Nonclinical Assessment of Anti-diabetic drugs27. Safety Assessments of Cancer Immunotherapy Drugs28. Application of Micro-physiological systems to enhance drug safety assessment29. Use of Humanized mice in Safety Assessment30. Safety Assessment of Cell and Gene Therapy31. Preclinical Development of Oncology Drugs32. Preclinical Toxicology of Vaccines33. Overview of the Nonclinical Development Strategies and Class-Effects of Oligonucleotide-Based TherapeuticsSection VII. Safety Evaluation of Ocular Drugs, Botanical Products, and Medicinal Devices34. Safety Evaluation of Ocular Drugs35. Safety Assessment of Targeted Protein Degraders (TBD)36. Biocompatibility Evaluation of Medical DevicesSection VIII. Predictive Toxicology, Toxicometabolomics, Toxicogenomics, and Imaging37. Application of Evolving Computational and Biological Platforms for Chemical Safety Assessment38. Use of Imaging for Preclinical Evaluation39. Drug Development Challenges and Opportunities Post-Pandemic
